Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:CRMDNASDAQ:MTSRNASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$62.01-3.0%$62.16$47.86▼$107.37$3.42B0.34599,554 shs302,292 shsCRMDCorMedix$12.43+0.6%$9.10$3.61▼$13.85$845.44M1.541.16 million shs1.12 million shsMTSRMetsera$28.61+4.8%$22.98$12.30▼$32.81$3.01BN/A888,533 shs506,343 shsRAREUltragenyx Pharmaceutical$35.14-1.5%$35.97$29.59▼$60.37$3.32B0.34872,695 shs414,964 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+9.25%+0.33%+2.03%+23.16%CRMDCorMedix0.00%-3.06%+35.82%+20.12%+141.41%MTSRMetsera0.00%-5.73%+47.33%-0.11%+2,729,999,900.00%RAREUltragenyx Pharmaceutical0.00%-1.46%-6.38%-12.60%-11.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.7889 of 5 stars3.50.00.00.03.42.50.0CRMDCorMedix2.1901 of 5 stars3.62.00.00.03.90.00.6MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical3.8488 of 5 stars3.51.00.03.83.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3379.56% UpsideCRMDCorMedix 3.14Buy$15.0020.68% UpsideMTSRMetsera 3.00Buy$47.0064.28% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$90.93158.77% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, RARE, ACLX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.003/25/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/17/2025RAREUltragenyx PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M44.49N/AN/A$9.97 per share6.22CRMDCorMedix$82.55M10.21N/AN/A$1.28 per share9.71MTSRMetseraN/AN/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical$590.69M5.62N/AN/A$2.76 per share12.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%8/14/2025 (Estimated)CRMDCorMedix-$46.34M$0.22N/A13.22N/AN/A-79.21%-64.68%8/13/2025 (Estimated)MTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%8/7/2025 (Estimated)Latest CRMD, RARE, ACLX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/A3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29CRMDCorMedixN/A3.963.60MTSRMetseraN/AN/AN/ARAREUltragenyx PharmaceuticalN/A2.372.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%CRMDCorMedix34.18%MTSRMetseraN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%CRMDCorMedix5.20%MTSRMetseraN/ARAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.70 millionOptionableCRMDCorMedix3067.83 million57.52 millionOptionableMTSRMetsera81105.06 millionN/AN/ARAREUltragenyx Pharmaceutical1,31094.54 million86.99 millionOptionableCRMD, RARE, ACLX, and MTSR HeadlinesRecent News About These CompaniesUltragenyx’s SWOT analysis: rare disease biotech stock poised for growthMay 26 at 11:56 PM | investing.comTwinbeech Capital LP Raises Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 24 at 4:53 AM | marketbeat.comTwo Sigma Investments LP Has $25.87 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 24 at 4:45 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Frazier Life Sciences Management L.P.May 23, 2025 | marketbeat.comBank of America Corp DE Has $16.34 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 23, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 74,300 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 22, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Vestal Point Capital LP's 5th Largest PositionMay 21, 2025 | marketbeat.comMillennium Management LLC Sells 13,453 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 21, 2025 | marketbeat.comSherbrooke Park Advisers LLC Acquires Shares of 10,387 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 20, 2025 | marketbeat.comMan Group plc Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 20, 2025 | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $90.93May 19, 2025 | americanbankingnews.comSphera Funds Management LTD. Has $9.63 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comPoint72 Hong Kong Ltd Grows Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc. Stock?May 16, 2025 | aaii.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $4.21 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 16, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $12.04 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc.: Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact ReportMay 15, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Keep Your EYE on This Stock, It Just Got a Rare Double UpgradeBy Sam Quirke | May 15, 2025View Keep Your EYE on This Stock, It Just Got a Rare Double UpgradeCRMD, RARE, ACLX, and MTSR Company DescriptionsArcellx NASDAQ:ACLX$62.00 -1.92 (-3.00%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.CorMedix NASDAQ:CRMD$12.43 +0.07 (+0.57%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Metsera NASDAQ:MTSR$28.61 +1.31 (+4.80%) As of 02:04 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Ultragenyx Pharmaceutical NASDAQ:RARE$35.14 -0.52 (-1.46%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
